ABVC BioPharma, Inc. Share Price
ABVCABVC BioPharma, Inc. Stock Performance
Open $2.01 | Prev. Close $2.06 | Circuit Range N/A |
Day Range $2.01 - $2.06 | Year Range $0.40 - $5.43 | Volume 999 |
Average Traded $2.03 |
ABVC BioPharma, Inc. Share Price Chart
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
ABVC BioPharma, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Jan-26 | $2.01 | $2.06 | -1.90% |
15-Jan-26 | $2.11 | $2.10 | +3.50% |
14-Jan-26 | $2.06 | $2.03 | -3.84% |
13-Jan-26 | $2.07 | $2.11 | +2.93% |
12-Jan-26 | $2.19 | $2.05 | -5.09% |
09-Jan-26 | $2.26 | $2.16 | -5.68% |
08-Jan-26 | $2.29 | $2.29 | -2.14% |